Trial Profile

The Xolair Pregnancy Registry: An Observational Study of the Use and Safety of Xolair (Omalizumab) During Pregnancy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omalizumab (Primary)
Indications Asthma
Focus Adverse reactions
Acronyms EXPECT
Sponsors Genentech

Most Recent Events

01 Mar 2021 Results (N=30) of post hoc analysis assessing the perinatal outcomes of patients enrolled in EXPECT who received Omalizumab for CSU during their pregnancy presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
27 May 2019 Results published in the Journal of Allergy and Clinical Immunology
25 Feb 2019 Results presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com